Line Listing Report Time run: 30/11/2022 03:07:41

EU Local Number	EV Gateway Receipt Date	Report Type	Primary Source Qualification	Primary Source Country for Regulatory Purposes	Literature Reference	Patient Age Group	Patient Age Group (as per reporter)	Sex	Parent Child Report	Reaction List PT (Duration – Outcome - Seriousness Criteria)	Suspect/interacting Drug List (Drug Char - Indication PT - Action taken - [Duration - Dose - Route])	Concomitant/Not Administered Drug List (Drug Char - Indication PT - Action taken - [Duration - Dose - Route])	ICSR Form
EU-EC- 10011328705	20/01/2022	Spontaneous	Healthcare	European Economic Area	Not available	0-1 Month	Adult	Male	No	Dizziness (0d - Recovered/Resolved -), Fatigue (1d - Recovering/Resolving -)	COMIRNATY [TOZINAMERAN] (S - Immunisation - n/a - [n/a - n/a - n/a])	Not reported	ICSR
EU-EC- 10011328782		Spontaneous	Healthcare Professional	European Economic Area	Not available	0-1 Month	Adult	Female	No	Chills (1d - Recovered/Resolved -), Dizziness (0d - Recovered/Resolved -), Fatigue (1d - Recovered/Resolved -), Injection site pain (2d - Recovering/Resolving -), Limb discomfort (1d - Recovered/Resolved -)	COMIRNATY [TOZINAMERAN] (S - Immunisation - n/a - [n/a - n/a - n/a])	Not reported	ICSR
EU-EC- 10011329337	20/01/2022	Spontaneous	Healthcare	European Economic Area	Not available	2 Months - 2 Years	Infant	Female	Yes	Diarrhoea (3d - Recovered/Resolved -)	COMIRNATY [TOZINAMERAN] (S - n/a - n/a - [n/a - n/a - Transmammary])	Not reported	ICSR
EU-EC- 10011330809	20/01/2022	Spontaneous	Healthcare	European Economic Area	Not available	2 Months - 2 Years	Adult	Male	No	Fatigue (0d - Recovering/Resolving -), Injection site pain (1d - Unknown -)	COMIRNATY [TOZINAMERAN] (S - Immunisation - n/a - [n/a - n/a - n/a])	Not reported	ICSR
EU-EC- 10011330934	20/01/2022	Spontaneous	Healthcare	European Economic Area	Not available	0-1 Month	Adult	Female	No	Chills (0d - Recovered/Resolved -), Fatigue (0d - Recovered/Resolved -), Limb discomfort (0d - Unknown -), Lymphadenopathy (1d - Not Recovered/Not Resolved -)	COMIRNATY [TOZINAMERAN] (S - Immunisation - n/a - [n/a - n/a - n/a])	Not reported	ICSR
EU-EC- 10011330984	20/01/2022	Spontaneous	Healthcare	European Economic Area	Not available	2 Months - 2 Years	Elderly	Female	No	Dizziness (1d - Not Recovered/Not Resolved -), Headache (0d - Recovered/Resolved -), Limb discomfort (1d - Not Recovered/Not Resolved -), Nausea (0d - Not Recovered/Not Resolved -)	COMIRNATY [TOZINAMERAN] (S - Immunisation - n/a - [n/a - n/a - n/a])	Not reported	ICSR
EU-EC- 10011330986	20/01/2022	Spontaneous	Non Healthcare Professional	European Economic Area	Not available	0-1 Month	Adult	Female	No	Chills (n/a - Unknown -), Fatigue (1d - Unknown -), Feeling hot (n/a - Unknown -), Headache (n/a - Unknown -), Limb discomfort (n/a - Unknown -), Malaise (n/a - Unknown -), Myalgia (n/a - Unknown -),	COMIRNATY [TOZINAMERAN] (S - Immunisation - n/a - [n/a - n/a - n/a])	Not reported	ICSR

.11.2022 00	J. 13	l	l	I	I	ı		 	Jung i	Nausea (n/a -	I	I	ı
EU-EC-	20/01/2022	Spontaneous	Non	European	Not	0-1	Adult	Female	No	Unknown -) Paraesthesia (n/a -	COMIRNATY	Not reported	ICSR
10011331748	20/01/2022	Spontaneous	Healthcare Professional	Economic	available	Month	Addit	remale	NO	Recovering/Resolving -),	[TOZINAMERAN] (S - Immunisation - n/a - [n/a - n/a -	Not reported	1031
										Visual impairment (0d - Recovered/Resolved -)	n/a])		
EU-EC- 10011332500	20/01/2022	Spontaneous	Non Healthcare	European Economic	Not available	2 Months	Infant	Female	No	Abdominal pain (n/a	COMIRNATY [TOZINAMERAN]	Not reported	ICSR
			Professional	Area		- 2 Years				Recovered/Resolved -), Crying (n/a -	(S - n/a - n/a - [n/a - n/a - n/a])		
										Recovered/Resolved -), Exposure via breast			
										milk (n/a - Recovered/Resolved -),			
										Rash (n/a - Recovered/Resolved -)			
EU-EC- 10011335840	20/01/2022	Spontaneous	Non Healthcare Professional	European Economic Area	Not available	0-1 Month	Infant	Female	No	Asthenia (2d - Recovered/Resolved -),	COMIRNATY [TOZINAMERAN] (S - COVID-19 immunisation - Not	Not reported	ICSR
FU FC	10/01/2022	Chantanagus	Non		Not	0.1	Not	Famala	No	Crying (2d - Recovered/Resolved -) Crying (21d -	applicable - [1d - 1{DF} - Intramuscular])	Not reported	ICCD
EU-EC- 10011309004	19/01/2022	Spontaneous	Healthcare Professional	European Economic Area	Not available	0-1 Month	Not Specified	Female	No	Recovering/Resolving -),	COMIRNATY [TOZINAMERAN] (S - COVID-19 immunisation - Not	Not reported	ICSR
										Fatigue (21d - Recovering/Resolving -),	applicable - [n/a - n/a - n/a])		
										Headache (21d - Recovering/Resolving -),			
										Initial insomnia (21d - Recovering/Resolving			
										-), Maternal exposure during breast feeding (21d -			
										Recovering/Resolving			
EU-EC- 10011309150	19/01/2022	Spontaneous	Non Healthcare Professional		Not available	2 Months - 2 Years	Not Specified	Female	Yes	Foetal exposure during pregnancy (n/a - Not Recovered/Not Resolved -	COMIRNATY [TOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a -	Not reported	ICSR
										Congenital Anomaly), Poor weight gain	n/a - n/a])		
										neonatal (n/a - Not Recovered/Not Resolved - Congenital Anomaly),			
										Thymus enlargement (n/a - Not Recovered/Not			
										Resolved - Caused/Prolonged Hospitalisation, Congenital Anomaly)			
EU-EC- 10011309924	19/01/2022	Spontaneous	Healthcare	European Economic	Not available	0-1 Month	Adult	Female	No	Fatigue (2d - Unknown -),	COMIRNATY [TOZINAMERAN]	Not reported	ICSR
			Professional	Area						Headache (2d - Unknown -),	(S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])		
										Nausea (2d - Unknown -)			
EU-EC- 10011309933	19/01/2022	Spontaneous	Healthcare	European Economic	Not available	2 Months - 2	Not Specified	Male	No		COMIRNATY [TOZINAMERAN] (S - COVID-19	Not reported	<u>ICSR</u>
			Professional	Area		Years				-), Asthenia (1d - Recovering/Resolving -),	immunisation - Not applicable - [n/a -		
										Headache (1d - Recovering/Resolving -),			
										Maternal exposure during breast feeding			
										(1d -			

J. 11.2022 US	3.13						Ru	n Line L	isting r	Кероп			
										Middle insomnia (1d			
										Recovering/Resolving -),			
										Myalgia (1d - Recovering/Resolving -),			
										Productive cough (1d			
										Recovering/Resolving -),			
										Screaming (1d - Recovering/Resolving -)			
EU-EC- 10011310598	19/01/2022	Spontaneous	Non Healthcare Professional	European Economic Area	Not available	2 Months - 2 Years	Not Specified	Male	Yes	Exposure via breast milk (n/a - Recovered/Resolved - Disabling),	COMIRNATY [TOZINAMERAN] (S - COVID-19 immunisation - Not	Not reported	ICSR
										Vomiting (n/a - Recovered/Resolved - Disabling)	applicable - [n/a - n/a - n/a])		
EU-EC- 10011311404	19/01/2022	Spontaneous	Non Healthcare	European Economic	Not available	2 Months	Not Specified	Male	No	Fatigue (n/a - Recovering/Resolving	COMIRNATY [TOZINAMERAN]	[TOPIRAMATE] (C - n/a - Unknown -	ICSR
			Professional			- 2 Years				- Caused/Prolonged Hospitalisation),	(S - COVID-19 immunisation - Not applicable - [n/a -	[n/a - 15mg -	
										Myalgia (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation),	n/a - n/a])	[VIGABATRIN] (C - n/a - Unknown - [n/a - 300mg - n/a])	
										Pyrexia (n/a - Recovering/Resolving - Caused/Prolonged Hospitalisation)			
EU-EC- 10011314567	19/01/2022	Spontaneous	Healthcare	European Economic Area	Not available	2 Months - 2 Years	Child	Female	No	Rash (97d - Not Recovered/Not Resolved -)	COMIRNATY [TOZINAMERAN] (S - Immunisation - n/a - [n/a - n/a - n/a])	Not reported	ICSR
EU-EC- 10011317064	19/01/2022	Spontaneous	Healthcare	European Economic Area	Not available	2 Months - 2	Infant	Female	Yes	Agitation (1d - Recovered/Resolved -),	COMIRNATY [TOZINAMERAN] (S - COVID-19	Not reported	ICSR
						Years				Crying (1d - Recovered/Resolved	immunisation - Not applicable - [1d - .3mL - Transmammary])		
										Vomiting projectile	, manismammary j		
										(1d - Recovered/Resolved -)			
EU-EC- 10011293128	18/01/2022	Spontaneous	Non Healthcare Professional	European Economic Area	Not available	0-1 Month	Not Specified	Female	No	Dizziness (15min - Recovered/Resolved -)	COMIRNATY [TOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - .3mL -	Not reported	ICSR
EU-EC- 10011298334	18/01/2022	Spontaneous	Healthcare Professional	European Economic	Not available	0-1 Month	Infant	Female	No	Arrhythmia neonatal	Intramuscular]) COMIRNATY [TOZINAMERAN]	Not reported	ICSR
10011298334			Professional	Area	avaijabje	Month				- Life Threatening),	(S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])		
										Recovering/Resolving Life Threatening),			
										Cardiac failure (n/a - Recovering/Resolving - Life Threatening),			
										Cardiogenic shock (n/a - Recovering/Resolving - Life Threatening),			
										Cardiovascular disorder (n/a - Recovering/Resolving - Life Threatening),			
										Foetal exposure during pregnancy			
										(n/a - Recovering/Resolving - Life Threatening),			
													1
										Neonatal asphyxia (n/a - Recovering/Resolving - Life Threatening)			

0.11.2022 0	3.13						Kui	1 Line Li	sung r	кероп			
										Maternal exposure during breast feeding (1d - Recovered/Resolved - Caused/Prolonged Hospitalisation), Nausea (1d - Recovered/Resolved - Caused/Prolonged Hospitalisation), Vomiting projectile (1d - Recovered/Resolved - Caused/Prolonged Hospitalisation)	applicable - [n/a - n/a - n/a])		
EU-EC- 10011301322	18/01/2022	Spontaneous	Non Healthcare Professional	European Economic Area	Not available	2 Months - 2 Years	Not Specified	Female	No	Abdominal pain (n/a - Recovering/Resolving - Disabling), Flatulence (n/a - Recovering/Resolving - Disabling), Maternal exposure during breast feeding (n/a - Recovering/Resolving - Disabling)	immunisation - Not applicable - [n/a - n/a - n/a])	Not reported	ICSR
EU-EC- 10011302687	18/01/2022	Spontaneous		European Economic Area	Not available	0-1 Month	Neonate (Preterm and Term newborns)	Not Specified	Yes	Regurgitation (4d - Recovered/Resolved -)	COMIRNATY [TOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - Oral])	Not reported	<u>ICSR</u>
EU-EC- 10011305530		Spontaneous	Non Healthcare	European Economic Area	Not available	2 Months - 2 Years	Infant	Male	Yes	Crying (3d - Recovered/Resolved -), Exposure via breast milk (n/a - Not Recovered/Not Resolved -), Eye swelling (0d - Recovered/Resolved -), Lacrimation increased (0d - Not Recovered/Not Resolved -), Mood altered (3d - Recovered/Resolved -), Rash erythematous (0d - Recovered/Resolved -), Rash erythematous (0d - Recovered/Resolved -), Rhinorrhoea (0d - Recovered/Resolved -) Exposure via breast milk (n/a - Not Recovered/Not Resolved -)	COMIRNATY [TOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Transmammary]) COMIRNATY [TOZINAMERAN]	Not reported	ICSR
10011303370			Professional		availusie	- 2 Years				Recovered/Not Resolved -), Vomiting (n/a - Recovering/Resolving -)	(S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} -		
EU-EC- 10011285508		Spontaneous	Healthcare Professional		Not available	0-1 Month	Infant	Not Specified	Yes	Crying (n/a - Recovered/Resolved -), Exposure via breast milk (n/a - Recovered/Resolved -), Vomiting (n/a - Recovered/Resolved -)	COMIRNATY [TOZINAMERAN] (S - n/a - n/a - [90d - n/a - n/a])	Not reported	ICSR
EU-EC- 10011288504		Spontaneous	Healthcare Professional	European Economic Area	Not available	0-1 Month	Adult	Female	No	Abdominal pain upper (n/a - Unknown -), Injection site pain (n/a - Unknown -), Malaise (n/a - Unknown -), Respiration abnormal (n/a - Unknown -) Poor feeding infant	COMIRNATY [TOZINAMERAN] (S - Immunisation - n/a - [n/a - n/a - n/a]) COMIRNATY	Not reported Not reported	ICSR
10011278184	15,01,2022	Sportaneous	Healthcare Professional	Economic	available		Specified	. IGIC		(n/a -	[TOZINAMERAN] (S - n/a - Not		<u>100K</u>

.11.2022 03	3.13						Rui	n Line Li	sting F	Report			
						- 2 Years				Recovered/Resolved	applicable - [n/a - n/a - Intramuscular]), COMIRNATY [TOZINAMERAN] (S - n/a - Not applicable - [n/a - n/a]), SPIKEVAX [COVID-19 MRNA VACCINE MODERNA (CX-024414)] (S - n/a - Not applicable - [n/a - n/a - n/a - Intramuscular])		
EU-EC- 10011263826	14/01/2022	Spontaneous	Non Healthcare Professional	European Economic Area	Not available	0-1 Month	Neonate (Preterm and Term newborns)	Female	Yes	Cloacal exstrophy (n/a - Not Recovered/Not Resolved - Life Threatening, Congenital Anomaly), Exposure during pregnancy (n/a - Not Recovered/Not Resolved - Life Threatening, Congenital Anomaly)	COMIRNATY [TOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])	Not reported	ICSR
EU-EC- 10011267321	14/01/2022	Spontaneous		European Economic Area	Not available	0-1 Month	Not Specified	Male	No	Asthenia (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation), Dyspnoea (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation), Feeling hot (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation), Hyperaesthesia (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation), Hypoaesthesia (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation), Hypoaesthesia (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation), Hypotonic- hyporesponsive episode (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation), Loss of consciousness (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation), Pain in extremity (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation), Pallor (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation), Seizure (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation), Seizure (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation), Syncope (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation), Syncope (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation), Visual impairment (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation), Visual impairment (n/a - Recovered/Resolved - Caused/Prolonged Hospitalisation), Vomiting (n/a -	COMIRNATY [TOZINAMERAN] (S - n/a - n/a - [n/a3mL - Intramuscular])	Not reported	ICSR

				l	I		I		Recovered/Resolved	I	I	
									- Caused/Prolonged			
EU-EC- 10011275888	14/01/2022	Spontaneous		Not available	2 Months - 2 Years	Infant	Male	No	Exposure via breast milk (n/a - Not Recovered/Not Resolved -), Skin discolouration (n/a - Recovered/Resolved -), Urticaria (n/a - Recovered/Resolved -), Urticaria (n/a - Recovering/Resolving -)	COMIRNATY [TOZINAMERAN] (S - COVID-19 immunisation - Dose not changed - [n/a - 1{DF} - Transmammary]), COMIRNATY [TOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Transmammary])	[ALUMINIUM, HAEMOPHILUS TYPE B CONJUGATE VACCINE (TETANUS TOXOID CONJUGATE), PERTUSSIS FILAMENTOUS HAEMAGGLUTININ, PERTUSSIS TOXOID ADSORBED ON ALUMINIUM HYDROXIDE, HYDRATED, TETANUS TOXOID ADSORBED ON ALUMINIUM HYDROXIDE, HYDRATED, DIPHTHERIA TOXOID ADSORBED ON ALUMINIUM HYDROXIDE, HYDRATED, DIPHTHERIA TOXOID ADSORBED ON ALUMINIUM HYDROXIDE, HYDRATED, POLIOVIRUS (INACTIVATED) TYPE 1 (MAHONEY STRAIN) PRODUCED ON VERO CELLS, POLIOVIRUS (INACTIVATED) TYPE 2 (MEF-1 STRAIN) PRODUCED ON VERO CELLS, POLIOVIRUS (INACTIVATED) TYPE 3 (SAUKETT STRAIN) PRODUCED ON VERO CELLS, POLIOVIRUS (INACTIVATED) TYPE 3 (SAUKETT STRAIN) PRODUCED ON VERO CELLS, POLIOVIRUS (INACTIVATED) TYPE B CONJUGATE VACCINE (TETANUS TOXOID CONJUGATE), PERTUSSIS FILAMENTOUS HAEMAGGLUTININ, POLIOVIRUS (INACTIVATED) TYPE 1 (MAHONEY STRAIN) PRODUCED ON VERO CELLS, POLIOVIRUS (INACTIVATED) TYPE 1 (MAHONEY STRAIN) PRODUCED ON VERO CELLS, POLIOVIRUS (INACTIVATED) TYPE 2 (MEF-1 STRAIN) PRODUCED ON VERO CELLS, POLIOVIRUS (INACTIVATED) TYPE 3 (SAUKETT STRAIN) PRODUCED ON VERO CELLS, POLIOVIRUS (INACTIVATED) TYPE 2 (MEF-1 STRAIN) PRODUCED ON VERO CELLS, POLIOVIRUS (INACTIVATED) TYPE 3 (SAUKETT STRAIN) PRODUCED ON VERO CELLS, POLIOVIRUS (INACTIVATED) TYPE 3 (SAUKETT STRAIN) PRODUCED ON VERO CELLS, POLIOVIRUS (INACTIVATED) TYPE B CONJUGATE VACCINE (TETANUS TOXOID CONJUGATE VACCINE (TETANUS TOXOI	

POLIOMYELITIS
VIRUS (INACTIVATED) TYPE 3 PRODUCED
TYPE 3 PRODUCED IN VERO CELLS,
FILAMENTOUS HAEMAGGLUTININ,
DIPHTHERIA
TOXOID, TETANUS TOXOID,
HAEMOPHILUS TYPE B
CONJUGATE
VACCINE (TETANUS TOXOID
CONJUGATE), PERTUSSIS
TOXOID,
PERTUSSIS FILAMENTOUS
HAEMAGGLUTININ, POLIOVIRUS TYPE
1 (INACTIVATED),
POLIOVIRUS TYPE 2 (INACTIVATED),
POLIOVIRUS TYPE 3 (INACTIVATED),
DIPHTHERIA
TOXOID, TETANUS TOXOID,
TOXOID, HAEMOPHILUS TYPE B
CONJUGATE
VACCINE (TETANUS TOXOID
CONJUGATE), PERTUSSIS
TOXOID,
PERTUSSIS FILAMENTOUS
HAEMAGGLUTININ, POLIOVIRUS TYPE
1 (INACTIVATED),
POLIOVIRUS TYPE 2 (INACTIVATED),
PÔLIOVIRUS TYPE 3 (INACTIVATED),
ALGELDRATE,
DIPHTHERIA TOXOID, TETANUS
TOXOID, HAEMOPHILUS
HACIMOPHILUS
TYPE B
TYPE B CONJUGATE
TYPE B CONJUGATE VACCINE (TETANUS TOXOID
TYPE B CONJUGATE VACCINE (TETANUS TOXOID CONJUGATE), PERTUSSIS
TYPE B CONJUGATE VACCINE (TETANUS TOXOID CONJUGATE), PERTUSSIS TOXOID.
TYPE B CONJUGATE VACCINE (TETANUS TOXOID CONJUGATE), PERTUSSIS TOXOID, PERTUSSIS
TYPE B CONJUGATE VACCINE (TETANUS TOXOID CONJUGATE), PERTUSSIS TOXOID, PERTUSSIS FILAMENTOUS HAEMAGGLUTININ, POI IOVIRUS TYPE
TYPE B CONJUGATE VACCINE (TETANUS TOXOID CONJUGATE), PERTUSSIS TOXOID, PERTUSSIS FILAMENTOUS HAEMAGGLUTININ, POLIOVIRUS TYPE 1 (INACTIVATED),
TYPE B CONJUGATE VACCINE (TETANUS TOXOID CONJUGATE), PERTUSSIS TOXOID, PERTUSSIS FILAMENTOUS HAEMAGGLUTININ, POLIOVIRUS TYPE 1 (INACTIVATED), POLIOVIRUS TYPE 2 (INACTIVATED),
TYPE B CONJUGATE VACCINE (TETANUS TOXOID CONJUGATE), PERTUSSIS TOXOID, PERTUSSIS FILAMENTOUS HAEMAGGLUTININ, POLIOVIRUS TYPE 1 (INACTIVATED), POLIOVIRUS TYPE 2 (INACTIVATED), POLIOVIRUS TYPE 3 (INACTIVATED),
TYPE B CONJUGATE VACCINE (TETANUS TOXOID CONJUGATE), PERTUSSIS TOXOID, PERTUSSIS FILAMENTOUS HAEMAGGLUTININ, POLIOVIRUS TYPE 1 (INACTIVATED), POLIOVIRUS TYPE 2 (INACTIVATED), POLIOVIRUS TYPE 3 (INACTIVATED), ALUMINIUM
TYPE B CONJUGATE VACCINE (TETANUS TOXOID CONJUGATE), PERTUSSIS TOXOID, PERTUSSIS FILAMENTOUS HAEMAGGLUTININ, POLIOVIRUS TYPE 1 (INACTIVATED), POLIOVIRUS TYPE 3 (INACTIVATED), ALUMINIUM HYDROXIDE, DIPHTHERIA
TYPE B CONJUGATE VACCINE (TETANUS TOXOID CONJUGATE), PERTUSSIS TOXOID, PERTUSSIS FILAMENTOUS HAEMAGGLUTININ, POLIOVIRUS TYPE 1 (INACTIVATED), POLIOVIRUS TYPE 3 (INACTIVATED), ALUMINIUM HYDROXIDE, DIPHTHERIA TOXOID, TETANUS TOXOID,
TYPE B CONJUGATE VACCINE (TETANUS TOXOID CONJUGATE), PERTUSSIS TOXOID, PERTUSSIS FILAMENTOUS HAEMAGGLUTININ, POLIOVIRUS TYPE 2 (INACTIVATED), POLIOVIRUS TYPE 3 (INACTIVATED), ALUMINIUM HYDROXIDE, DIPHTHERIA TOXOID, TETANUS TOXOID, HAEMOPHILUS
TYPE B CONJUGATE VACCINE (TETANUS TOXOID CONJUGATE), PERTUSSIS TOXOID, PERTUSSIS FILAMENTOUS HAEMAGGLUTININ, POLIOVIRUS TYPE 1 (INACTIVATED), POLIOVIRUS TYPE 3 (INACTIVATED), ALUMINIUM HYDROXIDE, DIPHTHERIA TOXOID, TETANUS TOXOID, HAEMOPHILUS TYPE B CONJUGATE
TYPE B CONJUGATE VACCINE (TETANUS TOXOID CONJUGATE), PERTUSSIS TOXOID, PERTUSSIS FILAMENTOUS HAEMAGGLUTININ, POLIOVIRUS TYPE 2 (INACTIVATED), POLIOVIRUS TYPE 3 (INACTIVATED), ALUMINIUM HYDROXIDE, DIPHTHERIA TOXOID, TETANUS TOXOID, HAEMOPHILUS TYPE B CONJUGATE VACCINE (TETANUS TOXOID
TYPE B CONJUGATE VACCINE (TETANUS TOXOID CONJUGATE), PERTUSSIS TOXOID, PERTUSSIS FILAMENTOUS HAEMAGGLUTININ, POLIOVIRUS TYPE 2 (INACTIVATED), POLIOVIRUS TYPE 3 (INACTIVATED), ALUMINIUM HYDROXIDE, DIPHTHERIA TOXOID, TETANUS TOXOID, HAEMOPHILUS TYPE B CONJUGATE VACCINE (TETANUS TOXOID CONJUGATE),
TYPE B CONJUGATE VACCINE (TETANUS TOXOID CONJUGATE), PERTUSSIS TOXOID, PERTUSSIS FILAMENTOUS HAEMAGGLUTININ, POLIOVIRUS TYPE 1 (INACTIVATED), POLIOVIRUS TYPE 3 (INACTIVATED), POLIOVIRUS TYPE 3 (INACTIVATED), ALUMINIUM HYDROXIDE, DIPHTHERIA TOXOID, TETANUS TOXOID, HAEMOPHILUS TYPE B CONJUGATE VACCINE (TETANUS TOXOID CONJUGATE), PERTUSSIS TOXOID,
TYPE B CONJUGATE VACCINE (TETANUS TOXOID CONJUGATE), PERTUSSIS TOXOID, PERTUSSIS FILAMENTOUS HAEMAGGLUTININ, POLIOVIRUS TYPE 2 (INACTIVATED), POLIOVIRUS TYPE 3 (INACTIVATED), ALUMINIUM HYDROXIDE, DIPHTHERIA TOXOID, TETANUS TOXOID, HAEMOPHILUS TYPE B CONJUGATE VACCINE (TETANUS TOXOID CONJUGATE), PERTUSSIS TOXOID, POLIOVIRUS TOXOID CONJUGATE VACCINE TETANUS TOXOID CONJUGATE), PERTUSSIS TOXOID, POLIOMYELITIS VIRUS
TYPE B CONJUGATE VACCINE (TETANUS TOXOID CONJUGATE), PERTUSSIS TOXOID, PERTUSSIS FILAMENTOUS HAEMAGGLUTININ, POLIOVIRUS TYPE 1 (INACTIVATED), POLIOVIRUS TYPE 2 (INACTIVATED), POLIOVIRUS TYPE 3 (INACTIVATED), ALUMINIUM HYDROXIDE, DIPHTHERIA TOXOID, TETANUS TOXOID, HAEMOPHILUS TYPE B CONJUGATE VACCINE (TETANUS TOXOID CONJUGATE), PERTUSSIS TOXOID, POLIOMYELITIS VIRUS (INACTIVATED)
TYPE B CONJUGATE VACCINE (TETANUS TOXOID CONJUGATE), PERTUSSIS TOXOID, PERTUSSIS FILAMENTOUS HAEMAGGLUTININ, POLIOVIRUS TYPE 2 (INACTIVATED), POLIOVIRUS TYPE 3 (INACTIVATED), POLIOVIRUS TYPE 3 (INACTIVATED), ALUMINIUM HYDROXIDE, DIPHTHERIA TOXOID, TETANUS TOXOID, HAEMOPHILUS TYPE B CONJUGATE VACCINE (TETANUS TOXOID CONJUGATE), PERTUSSIS TOXOID, POLIOWIGUSTIPS VIRUS (INACTIVATED) TYPE 1 PRODUCED IN VERO CELLS,
TYPE B CONJUGATE VACCINE (TETANUS TOXOID CONJUGATE), PERTUSSIS TOXOID, PERTUSSIS FILAMENTOUS HAEMAGGLUTININ, POLIOVIRUS TYPE 1 (INACTIVATED), POLIOVIRUS TYPE 2 (INACTIVATED), POLIOVIRUS TYPE 3 (INACTIVATED), ALUMINIUM HYDROXIDE, DIPHTHERIA TOXOID, HAEMOPHILUS TYPE B CONJUGATE VACCINE (TETANUS TOXOID CONJUGATE), PERTUSSIS TOXOID, POLIOMYELITIS VIRUS (INACTIVATED) IN VERO CELLS, POLIOMYELITIS VIRUS VIRUS
TYPE B CONJUGATE VACCINE (TETANUS TOXOID CONJUGATE), PERTUSSIS TOXOID, PERTUSSIS FILAMENTOUS HAEMAGGLUTININ, POLIOVIRUS TYPE 1 (INACTIVATED), POLIOVIRUS TYPE 3 (INACTIVATED), ALUMINIUM HYDROXIDE, DIPHTHERIA TOXOID, TETANUS TOXOID, HAEMOPHILUS TYPE B CONJUGATE VACCINE (TETANUS TOXOID CONJUGATE), PERTUSSIS TOXOID, PERTUSSIS TOXOID, POLIOMYELITIS VIRUS (INACTIVATED) TYPE 1 PRODUCED IN VERO CELLS, POLIOMYELITIS
TYPE B CONJUGATE VACCINE (TETANUS TOXOID CONJUGATE), PERTUSSIS TOXOID, PERTUSSIS FILAMENTOUS HAEMAGGLUTININ, POLIOVIRUS TYPE 1 (INACTIVATED), POLIOVIRUS TYPE 3 (INACTIVATED), ALUMINIUM HYDROXIDE, DIPHTHERIA TOXOID, TETANUS TOXOID, HAEMOPHILUS TYPE B CONJUGATE VACCINE (TETANUS TOXOID CONJUGATE), PERTUSSIS TOXOID, PERTUSSIS TOXOID, POLIOMYELITIS VIRUS (INACTIVATED) TYPE 1 PRODUCED IN VERO CELLS, POLIOMYELITIS VIRUS (INACTIVATED) TYPE 2 PRODUCED IN VERO CELLS,
TYPE B CONJUGATE VACCINE (TETANUS TOXOID CONJUGATE), PERTUSSIS TOXOID, PERTUSSIS FILAMENTOUS HAEMAGGLUTININ, POLIOVIRUS TYPE 2 (INACTIVATED), POLIOVIRUS TYPE 3 (INACTIVATED), ALUMINIUM HYDROXIDE, DIPHTHERIA TOXOID, TETANUS TOXOID, HAEMOPHILUS TYPE B CONJUGATE VACCINE (TETANUS TOXOID CONJUGATE), PERTUSSIS TOXOID, POLIOVIRUS TYPE IN TOXOID, HORDON TOXOID CONJUGATE VACCINE (TETANUS TOXOID CONJUGATE), PERTUSSIS TOXOID, POLIOMYELITIS VIRUS (INACTIVATED) TYPE 1 PRODUCED IN VERO CELLS, POLIOMYELITIS VIRUS (INACTIVATED) TYPE 2 PRODUCED IN VERO CELLS, POLIOMYELITIS VIRUS (INACTIVATED) TYPE 2 PRODUCED IN VERO CELLS, POLIOMYELITIS VIRUS (INACTIVATED) TYPE 2 PRODUCED IN VERO CELLS, POLIOMYELITIS VIRUS (INACTIVATED) TYPE 2 PRODUCED IN VERO CELLS, POLIOMYELITIS VIRUS
TYPE B CONJUGATE VACCINE (TETANUS TOXOID CONJUGATE), PERTUSSIS TOXOID, PERTUSSIS FILAMENTOUS HAEMAGGLUTININ, POLIOVIRUS TYPE 2 (INACTIVATED), POLIOVIRUS TYPE 3 (INACTIVATED), ALUMINIUM HYDROXIDE, DIPHTHERIA TOXOID, TETANUS TOXOID, HAEMOPHILUS TYPE B CONJUGATE VACCINE (TETANUS TOXOID CONJUGATE), PERTUSSIS TOXOID, POLIOVIRUS TYPE IN TOXOID, HORDON TOXOID CONJUGATE VACCINE (TETANUS TOXOID CONJUGATE), PERTUSSIS TOXOID, POLIOMYELITIS VIRUS (INACTIVATED) TYPE 1 PRODUCED IN VERO CELLS, POLIOMYELITIS VIRUS (INACTIVATED) TYPE 2 PRODUCED IN VERO CELLS, POLIOMYELITIS VIRUS (INACTIVATED) TYPE 2 PRODUCED IN VERO CELLS, POLIOMYELITIS VIRUS (INACTIVATED) TYPE 2 PRODUCED IN VERO CELLS, POLIOMYELITIS VIRUS (INACTIVATED) TYPE 2 PRODUCED IN VERO CELLS, POLIOMYELITIS VIRUS
TYPE B CONJUGATE VACCINE (TETANUS TOXOID CONJUGATE), PERTUSSIS TOXOID, PERTUSSIS FILAMENTOUS HAEMAGGLUTININ, POLIOVIRUS TYPE 1 (INACTIVATED), POLIOVIRUS TYPE 2 (INACTIVATED), POLIOVIRUS TYPE 3 (INACTIVATED), ALUMINIUM HYDROXIDE, DIPHTHERIA TOXOID, TETANUS TOXOID, HAEMOPHILUS TYPE B CONJUGATE VACCINE (TETANUS TOXOID CONJUGATE), PERTUSSIS TOXOID, POLIOMYELITIS VIRUS (INACTIVATED) TYPE 1 PRODUCED IN VERO CELLS, POLIOMYELITIS VIRUS (INACTIVATED) TYPE 2 PRODUCED IN VERO CELLS, POLIOMYELITIS VIRUS (INACTIVATED) TYPE 2 PRODUCED IN VERO CELLS, POLIOMYELITIS VIRUS (INACTIVATED) TYPE 2 PRODUCED IN VERO CELLS, POLIOMYELITIS VIRUS (INACTIVATED) TYPE 3 PRODUCED IN VERO CELLS, POLIOMYELITIS VIRUS (INACTIVATED) TYPE 3 PRODUCED IN VERO CELLS, POLIOMYELITIS VIRUS (INACTIVATED) TYPE 3 PRODUCED IN VERO CELLS,
TYPE B CONJUGATE VACCINE (TETANUS TOXOID CONJUGATE), PERTUSSIS TOXOID, PERTUSSIS FILAMENTOUS HAEMAGGLUTININ, POLIOVIRUS TYPE 2 (INACTIVATED), POLIOVIRUS TYPE 3 (INACTIVATED), ALUMINIUM HYDROXIDE, DIPHTHERIA TOXOID, TETANUS TOXOID, HAEMOPHILUS TYPE B CONJUGATE VACCINE (TETANUS TOXOID CONJUGATE), PERTUSSIS TOXOID, POLIOWIGHTIS VIRUS (INACTIVATED) TYPE 1 PRODUCED IN VERO CELLS, POLIOMYELITIS VIRUS (INACTIVATED) TYPE 2 PRODUCED IN VERO CELLS, POLIOMYELITIS VIRUS (INACTIVATED) TYPE 2 PRODUCED IN VERO CELLS, POLIOMYELITIS VIRUS (INACTIVATED) TYPE 3 PRODUCED IN VERO CELLS, POLIOMYELITIS VIRUS (INACTIVATED) TYPE 3 PRODUCED IN VERO CELLS, ALUMINIUM HYDROXIDE,
TYPE B CONJUGATE VACCINE (TETANUS TOXOID CONJUGATE), PERTUSSIS TOXOID, PERTUSSIS FILAMENTOUS HAEMAGGLUTININ, POLIOVIRUS TYPE 1 (INACTIVATED), POLIOVIRUS TYPE 3 (INACTIVATED), POLIOVIRUS TYPE 3 (INACTIVATED), ALUMINIUM HYDROXIDE, DIPHTHERIA TOXOID, TETANUS TOXOID, HAEMOPHILUS TYPE B CONJUGATE VACCINE (TETANUS TOXOID CONJUGATE), PERTUSSIS TOXOID, POLIOMYELITIS VIRUS (INACTIVATED) TYPE 1 PRODUCED IN VERO CELLS, POLIOMYELITIS VIRUS (INACTIVATED) TYPE 2 PRODUCED IN VERO CELLS, POLIOMYELITIS VIRUS (INACTIVATED) TYPE 2 PRODUCED IN VERO CELLS, POLIOMYELITIS VIRUS (INACTIVATED) TYPE 3 PRODUCED IN VERO CELLS, POLIOMYELITIS VIRUS (INACTIVATED) TYPE 3 PRODUCED IN VERO CELLS, POLIOMYELITIS VIRUS (INACTIVATED) TYPE 3 PRODUCED IN VERO CELLS, POLIOMYELITIS VIRUS (INACTIVATED) TYPE 3 PRODUCED IN VERO CELLS, ALUMINIUM HYDROXIDE, FILAMENTOUS
TYPE B CONJUGATE VACCINE (TETANUS TOXOID CONJUGATE), PERTUSSIS TOXOID, PERTUSSIS FILAMENTOUS HAEMAGGLUTININ, POLIOVIRUS TYPE 2 (INACTIVATED), POLIOVIRUS TYPE 3 (INACTIVATED), ALUMINIUM HYDROXID, HAEMOPHILUS TYPE B CONJUGATE VACCINE (TETANUS TOXOID, CONJUGATE VACCINE (TETANUS TOXOID CONJUGATE), PERTUSSIS TOXOID, POLIOMYELITIS VIRUS (INACTIVATED) TYPE 1 PRODUCED IN VERO CELLS, POLIOMYELITIS VIRUS (INACTIVATED) TYPE 2 PRODUCED IN VERO CELLS, POLIOMYELITIS VIRUS (INACTIVATED) TYPE 3 PRODUCED IN VERO CELLS, POLIOMYELITIS VIRUS (INACTIVATED) TYPE 3 PRODUCED IN VERO CELLS, POLIOMYELITIS VIRUS (INACTIVATED) TYPE 3 PRODUCED IN VERO CELLS, ALUMINIUM HYDROXIDE, FILAMENTOUS HAEMAGGLUTININ, DIPHTHERIA
TYPE B CONJUGATE VACCINE (TETANUS TOXOID CONJUGATE), PERTUSSIS TOXOID, PERTUSSIS FILAMENTOUS HAEMAGGLUTININ, POLIOVIRUS TYPE 1 (INACTIVATED), POLIOVIRUS TYPE 2 (INACTIVATED), POLIOVIRUS TYPE 3 (INACTIVATED), ALUMINIUM HYDROXIDE, DIPHTHERIA TOXOID, TETANUS TOXOID, HAEMOPHILUS TYPE B CONJUGATE VACCINE (TETANUS TOXOID CONJUGATE), PERTUSSIS TOXOID, POLIOMYELITIS VIRUS (INACTIVATED) TYPE 1 PRODUCED IN VERO CELLS, POLIOMYELITIS VIRUS (INACTIVATED) TYPE 2 PRODUCED IN VERO CELLS, POLIOMYELITIS VIRUS (INACTIVATED) TYPE 2 PRODUCED IN VERO CELLS, POLIOMYELITIS VIRUS (INACTIVATED) TYPE 3 PRODUCED IN VERO CELLS, POLIOMYELITIS VIRUS (INACTIVATED) TYPE 3 PRODUCED IN VERO CELLS, POLIOMYELITIS VIRUS (INACTIVATED) TYPE 3 PRODUCED IN VERO CELLS, POLIOMYELITIS VIRUS (INACTIVATED) TYPE 3 PRODUCED IN VERO CELLS, POLIOMYELITIS VIRUS (INACTIVATED) TYPE 3 PRODUCED IN VERO CELLS, POLIOMYELITIS VIRUS (INACTIVATED) TYPE 3 PRODUCED IN VERO CELLS, POLIOMYELITIS VIRUS (INACTIVATED) TYPE 3 PRODUCED IN VERO CELLS, POLIOMYELITIS VIRUS (INACTIVATED) TYPE 3 PRODUCED IN VERO CELLS, POLIOMYELITIS VIRUS (INACTIVATED) TYPE 3 PRODUCED IN VERO CELLS, POLIOMYELITIS VIRUS (INACTIVATED) TYPE 3 PRODUCED IN VERO CELLS, POLIOMYELITIS VIRUS (INACTIVATED) TYPE 3 PRODUCED IN VERO CELLS, POLIOMYELITIS VIRUS (INACTIVATED) TYPE 3 PRODUCED IN VERO CELLS, POLIOMYELITIS VIRUS (INACTIVATED) TYPE 3 PRODUCED IN VERO CELLS, POLIOMYELITIS VIRUS (INACTIVATED) TYPE 3 PRODUCED IN VERO CELLS, POLIOMYELITIS VIRUS (INACTIVATED) TYPE 3 PRODUCED IN VERO CELLS, POLIOMYELITIS VIRUS (INACTIVATED) TYPE 3 PRODUCED IN VERO CELLS, POLIOMYELITIS VIRUS (INACTIVATED) TYPE 3 PRODUCED IN VERO CELLS, POLIOMYELITIS VIRUS (INACTIVATED) TYPE 3 PRODUCED IN VERO CELLS, POLIOMYELITIS VIRUS (INACTIVATED) TYPE 3 PRODUCED IN VERO CELLS, POLIOMYELITIS VIRUS (INACTIVATED) TYPE 3 PRODUCED IN VERO CELLS, POLIOMYELITIS VIRUS (INACTIVATED) TYPE 3 PRODUCED IN VERO CELLS, POLIOMYELITIS VIRUS

													TYPE B CONJUGATE	
														1 1
													VACCINE (TETANUS TOXOID	
													CONJUGATE), PERTUSSIS	
													TOXOID, POLIOMYELITIS	
													VIRUS	
													(INACTIVATED) TYPE 1 PRODUCED	
													IN VERO CELLS, POLIOMYELITIS	
													VIRUS (INACTIVATED)	
													TYPE 2 PRODUCED IN VERO CELLS,	
													POLIOMYELITIS VIRUS	
													(INACTIVATED) TYPE 3 PRODUCED	
													IN VERO CELLS,	
													PERTUSSIS FILAMENTOUS	
													HAEMAGGLUTININ, ALUMINIUM	
													HYDROXIDE, DIPHTHERIA	
													TOXOID, TETANUS TOXOID,	
													HAEMOPHILUS TYPE B	
													CONJUGATE VACCINE	
													(TETANUS TOXOID	
													CONJUGATE), PERTUSSIS	
													TOXOID, POLIOVIRUS	
													(INACTIVATED) TYPE 1 (MAHONEY	
													STRAIN) PRODUCED ON	
													VERO CELLS, POLIOVIRUS	
													(INACTIVATED) TYPE 2 (MEF-1	
													STRAIN) PRODUCED ON	
													VERO CELLS, POLIOVIRUS	
													(INACTIVATED)	
													TYPE 3 (SAUKETT STRAIN)	
													PRODUCED ON VERO CELLS,	
													ALUMINIUM HYDROXIDE,	
													FILAMENTOUS HAEMAGGLUTININ,	
													DIPHTHERIA TOXOID, TETANUS	
													TOXOID, HAEMOPHILUS	
													TYPE B CONJUGATE	
													VACCINE (TETANUS TOXOID	
													CONJUGATE), PERTUSSIS	
													TOXOID, POLIOVIRUS TYPE	
													1 (INACTIVATED),	
													POLIOVIRUS TYPE 2 (INACTIVATED),	
													POLIOVIRUS TYPE 3 (INACTIVATED),	
													ALUMINIUM HYDROXIDE,	
													FILAMENTOUS HAEMAGGLUTININ,	
													DIPHTHERIA TOXOID, TETANUS	
													TOXOID, PERTUSSIS	
													TOXOID, PERTUSSIS	
													FILAMENTOUS HAEMAGGLUTININ,	
													POLIOVIRUS TYPE 1 (INACTIVATED),	
													POLIOVIRUS TYPE 2 (INACTIVATED),	
													POLIOVIRUS TYPE	
													3 (INACTIVATED)] (C - n/a - n/a - [n/a	
		13/01/2022	Spontaneous		European	Not	2	Child	Female	No	Influenza (n/a - Not	COMIRNATY	- n/a - n/a]) Not reported	ICSR
1	0011249007			Healthcare Professional	Economic Area	available	Months - 2				Recovered/Not Resolved -)	[TOZINAMERAN] (S - Immunisation		
							Years					- n/a - [n/a - n/a - n/a])		
E	U-EC-	13/01/2022	Spontaneous	Non	European	Not	0-1	Adult	Female	No	Fatigue (n/a -	COMIRNATY	Not reported	<u>ICSR</u>

0.11.2022 03	.13						ixu	n Line Li	sung i	report			
10011249921			Healthcare Professional	Economic Area	available	Month				Recovering/Resolving -), Injection site pain (1d - Recovering/Resolving -), Nausea (1d - Recovering/Resolving	[TOZINAMERAN] (S - Immunisation - n/a - [n/a - n/a - n/a])		
EU-EC- 10011258057	13/01/2022	Spontaneous	Non Healthcare Professional	European Economic Area	Not available	2 Months - 2 Years	Infant	Female	No	Diffuse alopecia (2mo - Recovered/Resolved -)	COMIRNATY [TOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Oral])	Not reported	ICSR
EU-EC- 10011258474	13/01/2022	Spontaneous	Healthcare Professional	European Economic Area	Not available	0-1 Month	Adult	Female	No	Dysgeusia (n/a - Recovered/Resolved -), Nausea (n/a - Recovered/Resolved -), Presyncope (n/a - Recovered/Resolved	COMIRNATY [TOZINAMERAN] (S - COVID-19 immunisation - Unknown - [n/a - 1{DF} - Intramuscular])	Not reported	ICSR
EU-EC- 10011228283	12/01/2022	Spontaneous	Non Healthcare Professional	European Economic Area	Not available	0-1 Month	Infant	Not Specified	Yes	Exposure via breast milk (1d - Recovered/Resolved -), Infant irritability (1d - Recovered/Resolved -), Somnolence (1d - Recovered/Resolved -)	COMIRNATY [TOZINAMERAN] (S - n/a - n/a - [n/a - n/a - Transmammary])	Not reported	ICSR
EU-EC- 10011230433	12/01/2022	Spontaneous	Non Healthcare Professional	European Economic Area	Not available	2 Months - 2 Years	Not Specified	Male	No	Exposure via breast milk (n/a - Not Recovered/Not Resolved -), Pyrexia (n/a - Not Recovered/Not Resolved -)	COMIRNATY [TOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])	Not reported	ICSR
EU-EC- 10011240981	12/01/2022	Spontaneous	Non Healthcare Professional	European Economic Area	Not available	0-1 Month	Adult	Female	No	Fatigue (2d - Unknown -), Limb discomfort (0d - Unknown -), Lymphadenopathy (n/a - Unknown -)	COMIRNATY [TOZINAMERAN] (S - Immunisation - n/a - [n/a - n/a - n/a])	Not reported	ICSR
EU-EC- 10011244232		Spontaneous	Professional	Non European Economic Area	Not available	- 2 Years	Not Specified		No	Chest pain (n/a - Not Recovered/Not Resolved -), Palpitations (n/a - Not Recovered/Not Resolved -), Pericarditis (n/a - Not Recovered/Not Resolved - Other Medically Important Condition), Product administered to patient of inappropriate age (n/a - Unknown -)	[TOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])	Not reported	ICSR
EU-EC- 10011213853	11/01/2022	Spontaneous	Healthcare	European Economic Area	Not available	2 Months - 2 Years	Infant	Male	No	Influenza like illness (3d - Not Recovered/Not Resolved - Caused/Prolonged Hospitalisation)	COMIRNATY [TOZINAMERAN] (S - Immunisation - n/a - [n/a - n/a - Intramuscular])	Not reported	<u>ICSR</u>
EU-EC- 10011215487	11/01/2022	Spontaneous	Non Healthcare Professional	European Economic Area	Not available	0-1 Month	Not Specified	Female	Yes	Abdominal pain (1d - Recovered/Resolved - Disabling), Fatigue (1d - Recovered/Resolved - Disabling), Maternal exposure during breast feeding (1d - Recovered/Resolved - Disabling), Nausea (1d - Recovered/Resolved - Disabling), Vomiting (1d - Recovered/Resolved - Disabling),	COMIRNATY [TOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])	Not reported	ICSR

30.11	.2022 03	3.13						Ru	n Line Li	isting F	Report			
EU-E	EC- 11202132	10/01/2022	Spontaneous	Non Healthcare Professional	Non European Economic Area	Not available	2 Months - 2 Years	Not Specified	Male	Yes	Discomfort (n/a - Not Recovered/Not Resolved - Other Medically Important Condition), Exposure via breast milk (n/a - Unknown - Other Medically Important Condition), Illness (n/a - Recovering/Resolving - Other Medically Important Condition), Infantile vomiting (n/a - Recovering/Resolving - Other Medically Important Condition), Infantile vomiting (n/a - Recovering/Resolving - Other Medically Important Condition)	COMIRNATY [TOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Transmammary])	Not reported	ICSR
	11202265		Spontaneous	Healthcare Professional		Not available	2 Months - 2 Years	Not Specified	Female	Yes	Exposure via breast milk (n/a - Recovered/Resolved -), Urticaria (n/a - Recovered/Resolved -)	COMIRNATY [TOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Transmammary])	IMEASLES VIRUS EDMONSTON- ENDERS STRAIN (LIVE, ATTENUATED) PRODUCED IN CHICK EMBRYO CELLS, MUMPS VIRUS RIT 4385 STRAIN (LIVE, ATTENUATED) DERIVED FROM FROM THE JERYL LYNN PRODUCED IN CHICK EMBRYO CELLS, RUBELLA VIRUS WISTAR RA 27/3 STRAIN (LIVE, ATTENUATED) PRODUCED IN HUMAN DIPLOID (MRC-5) CELLS, MEASLES VIRUS EDMONSTON- ENDERS STRAIN (LIVE, ATTENUATED) PRODUCED IN CHICK EMBRYO CELLS, RUBELLA VIRUS WISTAR RA 27/3 STRAIN (LIVE, ATTENUATED) PRODUCED IN CHICK EMBRYO CELLS, RUBELLA VIRUS WISTAR RA 27/3 STRAIN (LIVE, ATTENUATED) PRODUCED IN HUMAN DIPLOID (MRC-5) CELLS, MUMPS VIRUS RIT 4385 STRAIN (LIVE, ATTENUATED), MEASLES VIRUS EDMONSTON- SCHWARZ STRAIN (LIVE, ATTENUATED) PRODUCED IN CHICK EMBRYO CELLS, MUMPS VIRUS RIT 4385 STRAIN (LIVE, ATTENUATED) PRODUCED IN CHICK EMBRYO CELLS, MUMPS VIRUS RIT 4385 STRAIN (LIVE, ATTENUATED) PRODUCED IN CHICK EMBRYO CELLS, MUMPS VIRUS RIT 4385 STRAIN (LIVE, ATTENUATED) PRODUCED IN CHICK EMBRYO CELLS, RUBELLA VIRUS WISTAR RA 27/3 STRAIN (LIVE, ATTENUATED) PRODUCED IN HUMAN DIPLOID (MRC-5) CELLS, MUMPS VIRUS RIT 4385 STRAIN (LIVE, ATTENUATED) PRODUCED IN HUMAN DIPLOID (MRC-5) CELLS, MUMPS VIRUS RIT 4385 STRAIN (LIVE, ATTENUATED) PRODUCED IN HUMAN DIPLOID (MRC-5) CELLS, MUMPS VIRUS RIT 4385 STRAIN (LIVE, ATTENUATED) PRODUCED IN HUMAN DIPLOID (MRC-5) CELLS, MUMPS VIRUS RIT 4385 STRAIN (LIVE, ATTENUATED) PRODUCED IN HUMAN DIPLOID (MRC-5) CELLS, MUMPS VIRUS RIT 4385 STRAIN (LIVE, ATTENUATED) PRODUCED IN HUMAN DIPLOID (MRC-5) CELLS, MUMPS VIRUS RIT 4385 STRAIN (LIVE, ATTENUATED) PRODUCED IN HUMAN DIPLOID (MRC-5) CELLS, MUMPS VIRUS RIT 4385 STRAIN (LIVE, ATTENUATED) PRODUCED IN HUMAN DIPLOID (MRC-5) CELLS, MUMPS VIRUS RIT 4385 STRAIN (LIVE, ATTENUATED) PRODUCED IN HUMAN DIPLOID HUMAN	ICSR
https:/	//dap.en	na.europa.	eu/analytics	s/saw.dll?G	òo									10/1

HUMAN DIPLOID (MRC-5) CELLS,
(MRC-5) CELLS,
MUMPS VIRUS RIT
4385 STRAIN,
DERIVED FROM JERYL LYNN
STRAIN (LIVE,
ATTENUATED),
MEASLES VIRUS
SCHWARZ STRAIN
(LIVE,
ATTENUATED), MUMPS VIRUS
(LIVE,
ATTENUATED),
RUBELLA VIRUS
(LIVE,
ÀTTENUATED),
MEASLES VIRUS
SCHWARZ STRAIN
(LIVE, ATTENUATED),
MUMPS VIRUS RIT
4385 STRAIN
(LIVE,
ATTENUATED)
DERIVED FROM
FROM THE JERYL
LYNN PRODUCED
IN CHICK EMBRYO CELLS, RUBELLA
VIRUS WISTAR RA
27/3 STRAIN
(LIVE,
ATTENUATED)
PRODUCED IN
HUMAN DIPLOID
(MRC-5) CELLS,
MEASLES VIRUS SCHWARZ STRAIN
(LIVE,
ATTENUATED),
RUBELLA VIRÚS
WISTAR RA 27/3
STRAIN (LIVE,
ATTENUATED)
PRODUCED IN HUMAN DIPLOID
(MRC-5) CELLS,
MUMPS VIRUS RIT
4385 STRAIN,
DERIVED FROM JERYL LYNN
STRAIN (LIVE,
ATTENUATED),
RUBELLA VIRUS
WISTAR RA 27/3
STRAIN (LIVE, ATTENUATED)
PRODUCED IN WI-
38 HUMAN
DIPLOID LUNG
FIBROBLASTS,
MEASLES VIRUS
SCHWARZ STRAIN
SCHWARZ STRAIN (LIVE,
SCHWARZ STRAIN (LIVE, ATTENUATED),
SCHWARZ STRAIN (LIVE,
SCHWARZ STRAIN (LIVE, ATTENUATED), MUMPS VIRUS RIT 4385 STRAIN, DERIVED FROM
SCHWARZ STRAIN (LIVE, ATTENUATED), MUMPS VIRUS RIT 4385 STRAIN, DERIVED FROM JERYL LYNN
SCHWARZ STRAIN (LIVE, ATTENUATED), MUMPS VIRUS RIT 4385 STRAIN, DERIVED FROM JERYL LYNN STRAIN (LIVE,
SCHWARZ STRAIN (LIVE, ATTENUATED), MUMPS VIRUS RIT 4385 STRAIN, DERIVED FROM JERYL LYNN STRAIN (LIVE, ATTENUATED),
SCHWARZ STRAIN (LIVE, ATTENUATED), MUMPS VIRUS RIT 4385 STRAIN, DERIVED FROM JERYL LYNN STRAIN (LIVE, ATTENUATED), RUBELLA VIRUS
SCHWARZ STRAIN (LIVE, ATTENUATED), MUMPS VIRUS RIT 4385 STRAIN, DERIVED FROM JERYL LYNN STRAIN (LIVE, ATTENUATED),
SCHWARZ STRAIN (LIVE, ATTENUATED), MUMPS VIRUS RIT 4385 STRAIN, DERIVED FROM JERYL LYNN STRAIN (LIVE, ATTENUATED), RUBELLA VIRUS WISTAR RA 27/3 STRAIN (LIVE, ATTENUATED), ATTENUATED),
SCHWARZ STRAIN (LIVE, ATTENUATED), MUMPS VIRUS RIT 4385 STRAIN, DERIVED FROM JERYL LYNN STRAIN (LIVE, ATTENUATED), RUBELLA VIRUS WISTAR RA 27/3 STRAIN (LIVE, ATTENUATED), MEASLES VIRUS
SCHWARZ STRAIN (LIVE, ATTENUATED), MUMPS VIRUS RIT 4385 STRAIN, DERIVED FROM JERYL LYNN STRAIN (LIVE, ATTENUATED), RUBELLA VIRUS WISTAR RA 27/3 STRAIN (LIVE, ATTENUATED), MEASLES VIRUS EDMONSTON-
SCHWARZ STRAIN (LIVE, ATTENUATED), MUMPS VIRUS RIT 4385 STRAIN, DERIVED FROM JERYL LYNN STRAIN (LIVE, ATTENUATED), RUBELLA VIRUS WISTAR RA 27/3 STRAIN (LIVE, ATTENUATED), MEASLES VIRUS EDMONSTON-ENDERS STRAIN
SCHWARZ STRAIN (LIVE, ATTENUATED), MUMPS VIRUS RIT 4385 STRAIN, DERIVED FROM JERYL LYNN STRAIN (LIVE, ATTENUATED), RUBELLA VIRUS WISTAR RA 27/3 STRAIN (LIVE, ATTENUATED), MEASLES VIRUS EDMONSTON-ENDERS STRAIN (LIVE, ATTENUATED)
SCHWARZ STRAIN (LIVE, ATTENUATED), MUMPS VIRUS RIT 4385 STRAIN, DERIVED FROM JERVL LYNN STRAIN (LIVE, ATTENUATED), RUBELLA VIRUS WISTAR RA 27/3 STRAIN (LIVE, ATTENUATED), MEASLES VIRUS EDMONSTON-ENDERS STRAIN (LIVE, ATTENUATED) PRODUCED IN
SCHWARZ STRAIN (LIVE, ATTENUATED), MUMPS VIRUS RIT 4385 STRAIN, DERIVED FROM JERYL LYNN STRAIN (LIVE, ATTENUATED), RUBELLA VIRUS WISTAR RA 27/3 STRAIN (LIVE, ATTENUATED), MEASLES VIRUS EDMONSTON-ENDERS STRAIN (LIVE, ATTENUATED) PRODUCED IN CHICK EMBRYO
SCHWARZ STRAIN (LIVE, ATTENUATED), MUMPS VIRUS RIT 4385 STRAIN, DERIVED FROM JERYL LYNN STRAIN (LIVE, ATTENUATED), RUBELLA VIRUS WISTAR RA 27/3 STRAIN (LIVE, ATTENUATED), MEASLES VIRUS EDMONSTON-ENDERS STRAIN (LIVE, ATTENUATED) PRODUCED IN CHICK EMBRYO CELLS, MUMPS
SCHWARZ STRAIN (LIVE, ATTENUATED), MUMPS VIRUS RIT 4385 STRAIN, DERIVED FROM JERYL LYNN STRAIN (LIVE, ATTENUATED), RUBELLA VIRUS WISTAR RA 27/3 STRAIN (LIVE, ATTENUATED), MEASLES VIRUS EDMONSTON- ENDERS STRAIN (LIVE, ATTENUATED) PRODUCED IN CHICK EMBRYO CELLS, MUMPS VIRUS RIT 4385
SCHWARZ STRAIN (LIVE, ATTENUATED), MUMPS VIRUS RIT 4385 STRAIN, DERIVED FROM JERYL LYNN STRAIN (LIVE, ATTENUATED), RUBELLA VIRUS WISTAR RA 27/3 STRAIN (LIVE, ATTENUATED), MEASLES VIRUS EDMONSTON- ENDERS STRAIN (LIVE, ATTENUATED) PRODUCED IN CHICK EMBRYO CELLS, MUMPS VIRUS RIT 4385 STRAIN (LIVE,
SCHWARZ STRAIN (LIVE, ATTENUATED), MUMPS VIRUS RIT 4385 STRAIN, DERIVED FROM JERYL LYNN STRAIN (LIVE, ATTENUATED), RUBELLA VIRUS WISTAR RA 27/3 STRAIN (LIVE, ATTENUATED), MEASLES VIRUS EDMONSTON- ENDERS STRAIN (LIVE, ATTENUATED) PRODUCED IN CHICK EMBRYO CELLS, MUMPS VIRUS RIT 4385 STRAIN (LIVE, ATTENUATED) DERIVED FROM
SCHWARZ STRAIN (LIVE, ATTENUATED), MUMPS VIRUS RIT 4385 STRAIN, DERIVED FROM JERYL LYNN STRAIN (LIVE, ATTENUATED), RUBELLA VIRUS WISTAR RA 27/3 STRAIN (LIVE, ATTENUATED), MEASLES VIRUS EDMONSTON-ENDERS STRAIN (LIVE, ATTENUATED) PRODUCED IN CHICK EMBRYO CELLS, MUMPS VIRUS RIT 4385 STRAIN (LIVE, ATTENUATED) DERIVED FROM FROM THE JERYL
SCHWARZ STRAIN (LIVE, ATTENUATED), MUMPS VIRUS RIT 4385 STRAIN, DERIVED FROM JERYL LYNN STRAIN (LIVE, ATTENUATED), RUBELLA VIRUS WISTAR RA 27/3 STRAIN (LIVE, ATTENUATED), MEASLES VIRUS EDMONSTON-ENDERS STRAIN (LIVE, ATTENUATED) PRODUCED IN CHICK EMBRYO CELLS, MUMPS VIRUS RIT 4385 STRAIN (LIVE, ATTENUATED) DERIVED FROM LEVE, ATTENUATED) DERIVED FROM LEVE, ATTENUATED) DERIVED FROM FROM THE JERYL LYNN PRODUCED
SCHWARZ STRAIN (LIVE, ATTENUATED), MUMPS VIRUS RIT 4385 STRAIN, DERIVED FROM JERYL LYNN STRAIN (LIVE, ATTENUATED), RUBELLA VIRUS WISTAR RA 27/3 STRAIN (LIVE, ATTENUATED), MEASLES VIRUS EDMONSTON-ENDERS STRAIN (LIVE, ATTENUATED) PRODUCED IN CHICK EMBRYO CELLS, MUMPS VIRUS RIT 4385 STRAIN (LIVE, ATTENUATED) DERIVED FROM FROM THE JERYL LYNN PRODUCED IN CHICK EMBRYO LIVE, ATTENUATED) DERIVED FROM FROM THE JERYL LYNN PRODUCED IN CHICK EMBRYO LIVE, ATTENUATED) DERIVED FROM FROM THE JERYL LYNN PRODUCED IN CHICK EMBRYO
SCHWARZ STRAIN (LIVE, ATTENUATED), MUMPS VIRUS RIT 4385 STRAIN, DERIVED FROM JERYL LYNN STRAIN (LIVE, ATTENUATED), RUBELLA VIRUS WISTAR RA 27/3 STRAIN (LIVE, ATTENUATED), MEASLES VIRUS EDMONSTON-ENDERS STRAIN (LIVE, ATTENUATED) PRODUCED IN CHICK EMBRYO CELLS, MUMPS VIRUS RIT 4385 STRAIN (LIVE, ATTENUATED) DERIVED FROM FROM THE JERYL LYNN PRODUCED IN CHICK EMBRYO LIVE, ATTENUATED) DERIVED FROM FROM THE JERYL LYNN PRODUCED IN CHICK EMBRYO LIVE, ATTENUATED) DERIVED FROM FROM THE JERYL LYNN PRODUCED IN CHICK EMBRYO
SCHWARZ STRAIN (LIVE, ATTENUATED), MUMPS VIRUS RIT 4385 STRAIN, DERIVED FROM JERYL LYNN STRAIN (LIVE, ATTENUATED), RUBELLA VIRUS WISTAR RA 27/3 STRAIN (LIVE, ATTENUATED), MEASLES VIRUS EDMONSTON-ENDERS STRAIN (LIVE, ATTENUATED) PRODUCED IN CHICK EMBRYO CELLS, MUMPS VIRUS RIT 4385 STRAIN (LIVE, ATTENUATED) DERIVED FROM FROM THE JERYL LYNN PRODUCED IN CHICK EMBRYO CELLS, RUBELLA VIRUS WISTAR RA 27/3 STRAIN (LIVE, ATTENUATED)
SCHWARZ STRAIN (LIVE, ATTENUATED), MUMPS VIRUS RIT 4385 STRAIN, DERIVED FROM JERYL LYNN STRAIN (LIVE, ATTENUATED), RUBELLA VIRUS WISTAR RA 27/3 STRAIN (LIVE, ATTENUATED), MEASLES VIRUS EDMONSTON-ENDERS STRAIN (LIVE, ATTENUATED) PRODUCED IN CHICK EMBRYO CELLS, MUMPS VIRUS RIT 4385 STRAIN (LIVE, ATTENUATED) DERIVED FROM FROM THE JERYL LYNN PRODUCED IN CHICK EMBRYO CELLS, RUBELLA VIRUS WISTAR RA 27/3 STRAIN (LIVE, ATTENUATED) DERIVED FROM FROM THE JERYL LYNN PRODUCED IN CHICK EMBRYO CELLS, RUBELLA VIRUS WISTAR RA 27/3 STRAIN (LIVE,
SCHWARZ STRAIN (LIVE, ATTENUATED), MUMPS VIRUS RIT 4385 STRAIN, DERIVED FROM JERYL LYNN STRAIN (LIVE, ATTENUATED), RUBELLA VIRUS WISTAR RA 27/3 STRAIN (LIVE, ATTENUATED), MEASLES VIRUS EDMONSTON-ENDERS STRAIN (LIVE, ATTENUATED) PRODUCED IN CHICK EMBRYO CELLS, MUMPS VIRUS RIT 4385 STRAIN (LIVE, ATTENUATED) DERIVED FROM THE JERYL LYNN PRODUCED IN CHICK EMBRYO CELLS, RUBELLA VIRUS WISTAR RA 27/3 STRAIN (LIVE, ATTENUATED) TROM THE JERYL LYNN PRODUCED IN CHICK EMBRYO CELLS, RUBELLA VIRUS WISTAR RA 27/3 STRAIN (LIVE, ATTENUATED),
SCHWARZ STRAIN (LIVE, ATTENUATED), MUMPS VIRUS RIT 4385 STRAIN, DERIVED FROM JERYL LYNN STRAIN (LIVE, ATTENUATED), RUBELLA VIRUS WISTAR RA 27/3 STRAIN (LIVE, ATTENUATED), MEASLES VIRUS EDMONSTON-ENDERS STRAIN (LIVE, ATTENUATED) PRODUCED IN CHICK EMBRYO CELLS, MUMPS VIRUS RIT 4385 STRAIN (LIVE, ATTENUATED) DERIVED FROM FROM THE JERYL LYNN PRODUCED IN CHICK EMBRYO CELLS, RUBELLA VIRUS WISTAR RA 27/3 STRAIN (LIVE, ATTENUATED) DERIVED FROM FROM THE JERYL LYNN PRODUCED IN CHICK EMBRYO CELLS, RUBELLA VIRUS WISTAR RA 27/3 STRAIN (LIVE, ATTENUATED), MEASLES VIRUS
SCHWARZ STRAIN (LIVE, ATTENUATED), MUMPS VIRUS RIT 4385 STRAIN, DERIVED FROM JERYL LYNN STRAIN (LIVE, ATTENUATED), RUBELLA VIRUS WISTAR RA 27/3 STRAIN (LIVE, ATTENUATED), MEASLES VIRUS EDMONSTON-ENDERS STRAIN (LIVE, ATTENUATED) PRODUCED IN CHICK EMBRYO CELLS, MUMPS VIRUS RIT 4385 STRAIN (LIVE, ATTENUATED) DERIVED FROM THE JERYL LYNN PRODUCED IN CHICK EMBRYO CELLS, RUBELLA VIRUS WISTAR RA 27/3 STRAIN (LIVE, ATTENUATED) TROM THE JERYL LYNN PRODUCED IN CHICK EMBRYO CELLS, RUBELLA VIRUS WISTAR RA 27/3 STRAIN (LIVE, ATTENUATED),
SCHWARZ STRAIN (LIVE, ATTENUATED), MUMPS VIRUS RIT 4385 STRAIN, DERIVED FROM JERYL LYNN STRAIN (LIVE, ATTENUATED), RUBELLA VIRUS WISTAR RA 27/3 STRAIN (LIVE, ATTENUATED), MEASLES VIRUS EDMONSTON-ENDERS STRAIN (LIVE, ATTENUATED) PRODUCED IN CHICK EMBRYO CELLS, MUMPS VIRUS RIT 4385 STRAIN (LIVE, ATTENUATED) DERIVED FROM FROM THE JERYL LYNN PRODUCED IN CHICK EMBRYO CELLS, RUBELLA VIRUS WISTAR RA 27/3 STRAIN (LIVE, ATTENUATED), MEASLES VIRUS SCHWARZ STRAIN (LIVE, ATTENUATED), ATTENUATED), MEASLES VIRUS SCHWARZ STRAIN (LIVE, ATTENUATED), ATTENUATED),
SCHWARZ STRAIN (LIVE, ATTENUATED), MUMPS VIRUS RIT 4385 STRAIN, DERIVED FROM JERYL LYNN STRAIN (LIVE, ATTENUATED), RUBELLA VIRUS WISTAR RA 27/3 STRAIN (LIVE, ATTENUATED), MEASLES VIRUS EDMONSTON-ENDERS STRAIN (LIVE, ATTENUATED) PRODUCED IN CHICK EMBRYO CELLS, MUMPS VIRUS RIT 4385 STRAIN (LIVE, ATTENUATED) DERIVED FROM FROM THE JERYL LYNN PRODUCED IN CHICK EMBRYO CELLS, RUBELLA VIRUS WISTAR RA 27/3 STRAIN (LIVE, ATTENUATED) DERIVED FROM FROM THE JERYL LYNN PRODUCED IN CHICK EMBRYO CELLS, RUBELLA VIRUS WISTAR RA 27/3 STRAIN (LIVE, ATTENUATED), MEASLES VIRUS SCHWARZ STRAIN (LIVE, ATTENUATED), MEASLES VIRUS SCHWARZ STRAIN (LIVE, ATTENUATED), MUMPS VIRUS RIT
SCHWARZ STRAIN (LIVE, ATTENUATED), MUMPS VIRUS RIT 4385 STRAIN, DERIVED FROM JERYL LYNN STRAIN (LIVE, ATTENUATED), RUBELLA VIRUS WISTAR RA 27/3 STRAIN (LIVE, ATTENUATED), MEASLES VIRUS EDMONSTON-ENDERS STRAIN (LIVE, ATTENUATED) PRODUCED IN CHICK EMBRYO CELLS, MUMPS VIRUS RIT 4385 STRAIN (LIVE, ATTENUATED) DERIVED FROM FROM THE JERYL LYNN PRODUCED IN CHICK EMBRYO CELLS, RUBELLA VIRUS WISTAR RA 27/3 STRAIN (LIVE, ATTENUATED), MEASLES VIRUS SCHWARZ STRAIN (LIVE, ATTENUATED), MEASLES VIRUS SCHWARZ STRAIN (LIVE, ATTENUATED), MEASLES VIRUS SCHWARZ STRAIN (LIVE, ATTENUATED), MUMPS VIRUS RIT 4385 STRAIN (LIVE, ATTENUATED), MUMPS VIRUS RIT 4385 STRAIN (LIVE, ATTENUATED), MUMPS VIRUS RIT 4385 STRAIN (LIVE)
SCHWARZ STRAIN (LIVE, ATTENUATED), MUMPS VIRUS RIT 4385 STRAIN, DERIVED FROM JERYL LYNN STRAIN (LIVE, ATTENUATED), RUBELLA VIRUS WISTAR RA 27/3 STRAIN (LIVE, ATTENUATED), MEASLES VIRUS EDMONSTON-ENDERS STRAIN (LIVE, ATTENUATED) PRODUCED IN CHICK EMBRYO CELLS, MUMPS VIRUS RIT 4385 STRAIN (LIVE, ATTENUATED) DERIVED FROM FROM THE JERYL LYNN PRODUCED IN CHICK EMBRYO CELLS, RUBELLA VIRUS WISTAR RA 27/3 STRAIN (LIVE, ATTENUATED) DERIVED FROM FROM THE JERYL LYNN PRODUCED IN CHICK EMBRYO CELLS, RUBELLA VIRUS WISTAR RA 27/3 STRAIN (LIVE, ATTENUATED), MEASLES VIRUS SCHWARZ STRAIN (LIVE, ATTENUATED), MEASLES VIRUS SCHWARZ STRAIN (LIVE, ATTENUATED), MUMPS VIRUS RIT

												ATTENUATED) DERIVED FROM FROM THE JERYL LYNN PRODUCED IN CHICK EMBRYO CELLS, RUBELLA VIRUS WISTAR RA 27/3 STRAIN (LIVE, ATTENUATED), MEASLES VIRUS SCHWARZ STRAIN (LIVE, ATTENUATED), MUMPS VIRUS RIT 4385 STRAIN, DERIVED FROM JERYL LYNN STRAIN (LIVE, ATTENUATED)] (C - n/a - n/a - [1d - n/a - n/a]), [VARICELLA VIRUS OKA/MERCK STRAIN (LIVE, ATTENUATED) VARICELLA VIRUS OKA/MERCK STRAIN (LIVE, ATTENUATED) PROBUCED IN HUMAN DIPLOID (MRC-5) CELLS] (C - n/a - n/a - [1d - n/a - n/a])	
EU-EC- 10011200041	09/01/2022	Spontaneous	Healthcare Professional	European Economic Area	Not available	0-1 Month	Not Specified	Male	No	Vaccination site pain (2d - Recovered/Resolved -)	COMIRNATY [TOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular])	Not reported	ICSR
EU-EC- 10011191829	07/01/2022	Spontaneous	Healthcare	European Economic Area	Not available	2 Months - 2 Years	Infant	Female	No	Crying (n/a - Not Recovered/Not Resolved - Disabling), Diarrhoea neonatal (n/a - Not Recovered/Not Resolved - Disabling, Other Medically Important Condition), Restlessness (n/a - Not Recovered/Not Resolved - Disabling)	COMIRNATY [TOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - n/a - n/a])	Not reported	ICSR
EU-EC- 10011193264		Spontaneous	Healthcare Professional	Non European Economic Area	Not available	- 2 Years	Not Specified	Female	Yes	Diarrhoea (n/a - Not Recovered/Not Resolved - Other Medically Important Condition), Exposure via breast milk (n/a - Unknown - Other Medically Important Condition), Faeces discoloured (n/a - Not Recovered/Not Resolved - Other Medically Important Condition), Illness (n/a - Not Recovered/Not Resolved - Other Medically Important Condition),	[TOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Transmammary - More in ICSR])		
EU-EC- 10011181271		Spontaneous	Healthcare Professional	European Economic Area	Not available	2 Months - 2 Years	Elderly	Female	No	Arthralgia (n/a - Not Recovered/Not Resolved -), Asthenia (n/a - Not Recovered/Not Resolved -), Chest pain (n/a - Not Recovered/Not Resolved -), Ear pain (n/a - Not Recovered/Not Resolved -), Pyrexia (n/a - Not Recovered/Not Resolved -),	COMIRNATY [TOZINAMERAN] (S - COVID-19 immunisation - n/a - [n/a3mL - Intramuscular])	[CAPTOPRIL] (C - Hypertension - n/a - [n/a - n/a - Oral]), [EXTRACT (1:11) OF GENTIAN ROOT CUT, VERBENA HERB CUT, COMMON SORREL HERB CUT, ELDER FLOWER RUBBED, PRIMULA FLOWER WITH CALYX CUT; (1:3:3:3:3), EXTRACTION SOLVENT: ETHANOL, 59% (V/V), GENTIAN ROOT, GENTIAN	12/1

0.11.2022 00							1 (0)	I LIIIE LI	oung i	(oport			
												ROOT, VERBENA HERB, COMMON SORREL HERB, PRIMULA FLOWER WITH CALYX, SAMBUCUS NIGRA FLOWER, RUMEX, GENTIANA LUTEA, SAMBUCUS NIGRA L, VERBENA, PRIMULA VERIS FLOWER, SAMBUCI FLOS, GENTIAN ROOT, PRIMULA FLOWERS, GARDEN SORREL HERB, VERBENA OFFICINALIS, SAMBUCI FLOS, GENTIAN ROOT, VERBENA HERB, VERBENA OFFICINALIS, SAMBUCI FLOS, GENTIAN ROOT, VERBENA HERB, VERBENA OFFICINALIS, SAMBUCI FLOS, GENTIAN ROOT, VERBENA HERB, VERBENA HERB, VERBENA HERB, COMMON SORREL HERB, PRIMULA FLOWER WITH CALYX] (C - Sinusitis - n/a - [n/a - n/a - Oral])	
EU-EC- 10011181938	06/01/2022	Spontaneous	Healthcare	European Economic Area	Not available	2 Months - 2 Years	Neonate (Preterm and Term newborns)	Female	No	Diarrhoea (n/a - Recovered/Resolved -), Pyrexia (36h - Recovered/Resolved -)	COMIRNATY [TOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - Intramuscular])	Not reported	ICSR
EU-EC- 10011185062	06/01/2022	Spontaneous	Non Healthcare Professional	European Economic Area	Not available	2 Months - 2 Years	Elderly	Female	No	Malaise (n/a - Not Recovered/Not Resolved -)	COMIRNATY [TOZINAMERAN] (S - Immunisation - n/a - [n/a - n/a - n/a])	Not reported	ICSR
EU-EC- 10011164089	05/01/2022	Spontaneous	Non Healthcare Professional	Non European Economic Area	Not available	2 Months - 2 Years	Not Specified	Not Specified	Yes	Exposure via breast milk (n/a - Unknown - Other Medically Important Condition), Screaming (0d - Recovered/Resolved - Other Medically	COMIRNATY [TOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - n/a - Transmammary])	Not reported	ICSR
EU-EC- 10011164534	05/01/2022	Spontaneous	Healthcare	European Economic Area	Not available	2 Months - 2 Years	Not Specified	Male	Yes	Important Condition) Exposure via breast milk (n/a - Unknown -), Pyrexia (n/a - Not Recovered/Not Resolved -), Pyrexia (n/a - Unknown -)	COMIRNATY [TOZINAMERAN] (S - Immunisation - n/a - [n/a - n/a - Transmammary])	Not reported	ICSR
EU-EC- 10011164570	05/01/2022	Spontaneous	Healthcare	European Economic Area	Not available	2 Months - 2 Years	Not Specified	Not Specified	Yes	Exposure via breast milk (n/a - Unknown -), Pyrexia (n/a - Not Recovered/Not Resolved -)	COMIRNATY [TOZINAMERAN] (S - Immunisation - n/a - [n/a - n/a - Transmammary])	Not reported	ICSR
EU-EC- 10011170831		Spontaneous	Professional	European Economic Area	Not available	0-1 Month	Not Specified	Male	No	Abdominal pain upper (n/a - Not Recovered/Not Resolved -), Exposure via breast milk (n/a - Unknown -), Rash (n/a - Not Recovered/Not Resolved -)	COMIRNATY [TOZINAMERAN] (S - Immunisation - n/a - [n/a - n/a - n/a])	Not reported	ICSR
EU-EC- 10011173809	U5/01/2022	Spontaneous	Healthcare Professional	European Economic Area	Not available	- 2 Years	Not Specified	Male	Yes	Abdominal pain (n/a - Recovered/Resolved -), Exposure via breast milk (n/a - Unknown -), Frequent bowel movements (n/a - Recovered/Resolved -), Restlessness (n/a - Recovered/Resolved -)	COMIRNATY [TOZINAMERAN] (S - Immunisation - n/a - [n/a - n/a - Transmammary])	Not reported	ICSR
EU-EC- 10011158927	04/01/2022	Spontaneous	Healthcare	European Economic Area	Not available	2 Months - 2 Years	Not Specified	Male	No	Exposure via breast milk (n/a - Unknown -), Haematochezia (n/a - Unknown -)	COMIRNATY [TOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [n/a - 1{DF} - n/a])	Not reported	ICSR
		Spontaneous eu/analytics			Not	0-1	Neonate	Female	Yes	Haemolytic anaemia	COMIRNATY	Not reported	ICSR 13/1

Run Line Listing Report

10011147467		Healthcare Professional	Economic Area	available	Month	(Preterm and Term newborns)			, , ,	[TOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Transplacental])			
EU-EC- 10011148013	03/01/2022		European Economic Area	Not available	2 Months - 2 Years	Infant	Male	No	Pyrexia (n/a - Recovered/Resolved -), Seizure (n/a - Recovered/Resolved -)	COMIRNATY [TOZINAMERAN] (S - COVID-19 immunisation - Not applicable - [1d - 1{DF} - Transmammary])	Not reported	<u>ICSR</u>	

↑ ↑ ↓ I Rows 501 - 557 (end)

<u>Return</u> - <u>Refresh</u> - <u>Print</u> - <u>Export</u>